US20030017111A1 - Fluorescent agents for real-time measurement of organ function - Google Patents

Fluorescent agents for real-time measurement of organ function Download PDF

Info

Publication number
US20030017111A1
US20030017111A1 US10228807 US22880702A US2003017111A1 US 20030017111 A1 US20030017111 A1 US 20030017111A1 US 10228807 US10228807 US 10228807 US 22880702 A US22880702 A US 22880702A US 2003017111 A1 US2003017111 A1 US 2003017111A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
molecule
agent
fluorescence
time
fluorescent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10228807
Inventor
Carlos Rabito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0028Oxazine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • A61K49/0034Indocyanine green, i.e. ICG, cardiogreen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds

Abstract

A fluorescent agent for monitoring organ function, such as glomerular filtration, renal blood flow, or hepatic function. The agent is injected into a subject and the fluorescence monitored in vivo via time-resolved fluorescent techniques. The agent is a lanthanide ion chelated to a polyaminopolyacetic acid analog. A new clearance agent is also proposed based on a tetraazamacrocycle. Such a clearance agent also finds applications in other fields where fluorescence detection is exploited.

Description

  • This application is a divisional application of U.S. application Ser. No. 09/631,138, filed Aug. 2, 2000 and now issued as U.S. Pat. No. 6,440,389, which claims priority from Provisional Application No. 60/219,362, filed Jul. 19, 2000. Both of these related applications are incorporated herein by reference.[0001]
  • FIELD OF THE INVENTION
  • This invention pertains to fluorescent agents, instruments, and techniques for measurement of organ function, and, more specifically, for real-time measurement of organ function. [0002]
  • BACKGROUND OF THE INVENTION
  • Acute renal failure (ARF), as a complication of multiple surgical, medical and obstetrical conditions, represents an important individual and public health problem. Early identification of patients at risk, with prompt elimination of potential insults, is a golden rule that has saved many lives. Unfortunately, despite close implementation of this rule, the disease still accounts for a large morbidity and mortality, with a survival rate of about 50%, a figure which has not substantially improved since 1950 (Butkus, D., [0003] Arch. Intern. Med., 143: 209-212, 1983). This poor outcome contrasts with the almost unique ability of the kidney to undergo virtually complete recovery of function following an episode of transient ischemia or toxin-induced cellular destruction. This discrepancy between mortality and the potential for reversibility emphasizes the need for a reconsideration of current diagnostic and therapeutic options with the goal of assuring complete recovery of organ function after an episode of ARF.
  • Because the clinical condition of patients with ARF is determined largely by prior health status and the nature of the specific insult that led to renal failure, any therapeutic approach used to treat ARF should be simultaneously oriented toward correcting the precipitating cause and the impaired organ function. Hypoperfusion of the kidney is the most frequently recognized single insult leading to ARF in the setting of trauma, surgery, hemorrhage, or dehydration (Kellen, M., S. Aronson, et al., [0004] Anesth. Analg., 78: 134-142, 1994; Hou, S., D. Bushinsky, et al., Am. J. Med., 74: 243-248, 1983). Continuous and precise monitoring of cardiopulmonary function in such acute settings has been available for many years and has undoubtedly helped to restore normal circulatory status in the critically ill patient. At the present time, however, monitoring of renal function is done with crude measurements such as urine output and plasma creatinine. Unfortunately, because of their lengthy resolution time (the time required to obtain a single measurement of renal function), none of these parameters can be used for real-time monitoring of renal function. For example, creatinine clearance measurements have a resolution of about 12 hours. By the time a patient's ARF was recognized by this technique, it would be too late to treat the patient and have any hope of saving the kidney. The inadequacy of standard techniques for monitoring renal function during critical care is the most salient limitation for prevention of ARF and for the determination of an appropriate therapy to correct organ failure.
  • Measurements of glomerular filtration rate (GFR) can be made directly by micropuncture or indirectly by clearance methods. Although direct techniques have produced major contributions in our understanding of the production and regulation of the glomerular ultrafiltrate in laboratory animals, the invasive nature of the procedures renders them of questionable value in humans. Clearance techniques, on the other hand, are normally used to measure renal function in humans. However, because the techniques have such lengthy resolution times, it is quite difficult to detect rapid changes in GFR that may occur under different physiological and pathological conditions. For instance, GFR changes during exercise (Barclay, J., W. Cooke, et al., [0005] J. Physiol. (London), 104: 14, 1946), with orthostatic hypotension (Papper, E. and S. Ngai, Ann. Rev. Med., 7: 213-224, 1956), and with changes in posture (Werko, L., H. Bucht, et al., Scand. J. Clin. Lab. Invest., 1: 321, 1949). The changes in GFR during exercise were only detected when the exercise level was very intense and the changes in cardiopulmonary function were quite persistent (Selkur, E., Handbook of Physiology: Circulation, J. Field, Ed. Washington, DC: Am. Physiol. Soc., Vol. 2, pp. 1457-1516, 1963). These results suggested that changes in GFR at low levels of exercise may have gone undetected due to the poor resolution time of the clearance techniques. In order to fully understand this important limitation of clearance techniques, one should ask how fast the changes in GFR might occur under an ideal experimental condition emulating a hypoperfusion event of the kidney. Studies performed in the isolated, perfused dog kidney indicate that sudden changes (within seconds) in perfusion pressure are very closely followed (also within a few seconds) by changes in GFR (Harvey, R., Circulation Res., 15: 178-182, 1964). Clearance techniques, on the other hand, have a totally different resolution time. It was recognized very early that a considerable interval (more than 30 minutes) is required for a sudden change in GFR to be initially detected in the composition of urine (Smith, H., The Kidney: Structure and Function in Health and Disease, New York: Oxford University Press, 1951). This time most likely represents the time required for the ultrafiltrate to pass down the tubules, collecting ducts, and ureters before it reaches and equilibrates with the urine already contained in the urinary bladder. Since at least two samples are needed to determine that the measurement is done at equilibrium, the minimal ideal resolution time for this procedure will be about 1 hour. This, plus the usual delay in measuring the concentration of an agent in urine and blood samples, represents a significant limitation in the use of this procedure for bedside, real-time, monitoring of renal function in patients with ARF.
  • Renal function has traditionally been measured by creatinine clearance. It is now recognized, however, that in addition to the technical problems with creatinine measurement and with urine collection, creatinine clearance is not an accurate measure of GFR (Carrie, B., H. Golbertz, et al., [0006] Am. J. Med., 69: 177-182, 1980; Price, M., J. Urol., 107: 339-340, 1972). Quantitative methods for measuring renal glomerular and tubular function with clearance techniques have been available for many years. The nonendogenously produced substance inulin probably meets the requirements of an ideal GFR agent (Smith, 1951). Although it has remained the “gold standard”, the chemical methods of measurement are unfortunately too cumbersome for routine use. In addition to seeking a substance that fulfills the requirements of a GFR agent, researchers have also sought to overcome the other major source of error in clearance measurements, namely, incomplete urine collection. Two approaches have been found to be successful. The most accurate, but technically difficult, is the constant infusion of a substance until an equilibrium is reached, at which point the plasma level is steady. The rate of infusion is then equal to the rate of loss in the urine and no urine collection is necessary (Earle, D. and R. Berliner, Proc. Soc. Exp. Biol. Med., 62: 262-264, 1946). Alternatively, the rate of plasma disappearance of a substance after a single intravenous injection is determined, enabling calculation of GFR (Sapirstein, L., D. Vidt, et al., Am. J. Physiol., 181: 330-336, 1955; Chantler, C. and T. Barratt, Archs. Dis. Child., 47: 613-617, 1972). The disappearance of the tracer is determined by taking multiple blood samples over a period of 3 to 4 hours and then measuring the radioactivity of the samples. In addition to the requirements that a GFR agent must be freely filtered by the glomerulus, four other basic criteria must apply if a substance is to be used to measure clearance without urine collection:
  • a. it must not be metabolized; [0007]
  • b. it must be cleared exclusively by glomerular filtration (no other route of excretion other than renal); [0008]
  • c. it must not be bound to plasma protein or extracellular components; and [0009]
  • d. it must not be reabsorbed by the nephron. [0010]
  • [0011] 51Cr-EDTA, 99Tc-DTPA, and 125I-sodium iothalamate meet these requirements and are the accepted choices for measuring GFR in most clinical studies (Chantler, 1972; Sigman, E., C. Ellwood, et al., J. Nucl. Med., 7: 60-68, 1965). Most of these clearance techniques, although more accurate than creatinine clearance, have not been widely used because of their technical complexities. Moreover, all of these methods are grossly inadequate for real-time and accurate monitoring of renal function. Clearly, a method for real-time, accurate, and continuous measurement of GFR in acute clinical settings will be a tremendous help in the management of patients who have ARF or are at risk of developing ARF.
  • Because glomerular filtration is the first step in urine production, the measurement of GFR represents the most convenient and reliable parameter for evaluation of renal function. Although there is general agreement that inulin clearance is the best measure of GFR, there are, as indicated above, several inherent difficulties in the use of this agent. As an alternative to inulin, a number of agents labeled with radioactive tracers have been introduced in the past few years for the measurement of GFR, including several chelates such as [0012] 51Cr-EDTA (Stacy, B. and G. Thorburn, Science, 152: 1076-1078, 1966), 111mIn-DTPA (Reba, R., F. Hosain, et al., Radiology, 90: 147-152, 1968), 169Yb-DTPA (Hosain, F., R. Reba, et al., Int. J. Appl. Radiat., 20: 517-524, 1969; Perrone, R., T. Stainman, et al., Am. J. Kidney Dis., 16: 224-235, 1990) and 140La-DTPA (Bianchi, C. and M. Blaufox, J. Nucl. Biol. Med., 12: 117-122, 1968). The introduction of a kit for rapid and simple preparation of 99mTc-DTPA has made this the most readily available agent used to measure GFR, either by blood clearance (Klopper, J., W. Hauser, et al., J. Nucl. Med., 13: 107-110, 1972; Barbour, G., C. Crumb, et al., J. Nucl. Med., 17: 317-320, 1976; Hilson, A., R. Mistry, et al., Br. J. Radiol., 49: 794-799, 1976) or by external detection (Blaufox, M., E. Potchen, et al., J. Nucl. Med., 8: 77-85, 1967; Cohen, M., J. Patel, et al., Pediatrics, 48: 377-391, 1971; Thirimurthi, K., M. Casey, et al., Nucl. Med. All. Sci., 28: 245-250, 1984).
  • Real-time monitoring of renal function: Taking advantage of this opportunity, we developed a new approach for noninvasive and real-time monitoring of renal function (Rabito, C., R. Moore, et al., [0013] J. Nucl. Med., 34: 199-207, 1993). The method is based on a variation of the single-injection technique (Donath, A., Acta. Pediatr. Scan., 60: 512-527, 1971), in which continuous and instantaneous measurement of radioactivity is performed with an external detector rather than with the intermittent and deferred assay of venous blood and is described more fully in our commonly owned patents, U.S. Pat. Nos. 5,647,363 and 5,301,673, the contents of which are incorporated herein by reference. A radiation detector attached to a miniature data logger was used to monitor the clearance of 99mTc-diethylene triamine pentaacetic acid (99mTc-DTPA) from the extracellular space (Rabito, 1993). After a short equilibration period, the system behaved as a compartment system with first order kinetics. In this system, the log of activity varies lineraly with time, with the rate constant given by the slope of the resulting line. Two important assumptions are involved in the use of this approach for monitoring renal function. The first assumption is that the measurement of the rate constant can be performed fast enough to approach real-time conditions. For instance, the slope or rate constant can be calculated from several consecutive measurements of activity performed for a few seconds during a short interval of only a few minutes. This rate constant can be updated every minute or less after entering each new individual measurement. The second assumption is that the measurement of the rate constant for the clearance of an “ideal” glomerular filtration agent from the extracellular space constitutes a precise and reproducible estimate of GFR. In the single injection technique, GFR is usually calculated as the volume of distribution of the GFR agent multiplied by the rate constant. However, because the volume distribution is assumed to be constant after normalization by body surface area, the rate constant per se represents an accurate estimate of GFR. These assumptions are supported by the excellent correlation between the rate constant for clearance of 99mTc-DTPA and simultaneous GFR measurements performed with a standard 125-iothalamate clearance technique in 50 patients with different degrees of renal dysfunction (FIG. 1).
  • Because of their limited resolution time, none of the current techniques to measure renal function could be used to demonstrate the improvement in the resolution time of this novel approach. As an alternative, we studied the response-time of the technique by using the device in patients undergoing a medical procedure with high incidence of ARF. The rationale was that, in the case of ARF, the instrument should closely follow any rapid change in the renal function that may take place during the event. Validation, however, could be performed by comparison with a standard clearance technique before and after the intervention and once the renal function has become stable. The procedure was used, for instance, to monitor renal function in patients at risk for ARF in the intensive care unit or during angiography. The results demonstrated that the technique detected rapid changes in renal function with a resolution time of as little as 2.5 to 5 min. (Rabito, 1993; Rabito, C., F. Panico, et al., [0014] J. Am. Soc. Nephrol., 4: 1421-1428, 1994; Rabito, C., L. Fang, et al., Radiology, 186: 851-854, 1993).
  • Although highly innovative, this technique has some limitations. First, due to strict regulations and high costs, not every physician or medical institution has access to the use of radioactive tracer techniques. Second, due to the risk of radiation exposure, the technique cannot be used to measure renal function during surgery, or in infants and pregnant or post-partum women. To overcome these limitations, we propose in this invention the development of fluorescent GFR and renal blood flow (RBF) agent to be used in conjunction with a fluorescence-activated renal monitor, to thereby eliminate the limitations of the current radioactive GFR and RBF agents. [0015]
  • SUMMARY OF THE INVENTION
  • It is an object of this invention to provide fluorescent agents to monitor specific functions in specific organs. [0016]
  • It is also an object of this invention to provide an instrument for standard and time-resolved transcutaneous fluorescence measurements of these agents. [0017]
  • It is a further object of this invention to provide a method for real-time measurement and monitoring of organ function determined from transcutaneous fluorescence measurements of these agents. [0018]
  • In one aspect, the invention is a method of detecting a clearance function in a subject. The method comprises providing an electroluminescent agent in a circulatory system of the subject, irradiating a tissue site with electromagnetic radiation having sufficient energy and intensity to be absorbed by the agent, detecting the intensity of emission from the tissue site, and repeating the step of detecting at known time intervals. The agent is not metabolized by the subject and is only cleared by a single mechanism. In addition, the agent does not bind plasma, protein, or extracellular components and is not reabsorbed by the subject. The method may further comprise irradiating the tissue site with a laser, for example, a pulsed laser. The step of repeating may be performed until elapsed time since the step of irradiating is about 90% of the decay time, for example, 50 ns or greater. After the step of detecting has been repeated a predetermined number of times, the step of irradiating may be repeated, and a background emission may have decayed to an insignificant level before the step of detecting is performed. [0019]
  • In one embodiment, the agent may be cleared exclusively by the glomerulus and may comprise a polyaminopolyacetic acid derivative conjugated with an electroluminescent moiety, which may comprise a lanthanide ion. The lanthanide ion may be trivalent and may comprise Ce[0020] +++, Nd+++, Sm+++, Eu+++, or Tb+++. The conjugate may exhibit fluorescence when irradiated with red or infrared light.
  • The polyaminopolyacetic acid derivative may be selected from diethylenetriaminepentaacetic acid (DTPA) ethylene glycol N,N,N′,N′-tetraacetic acid (EGTA), or polyaminopolybis(2-aminoethyl ether) acetic acid. The polyaminopolyacetic acid derivative may comprise [0021]
    Figure US20030017111A1-20030123-C00001
  • S may be a cyclic organic moiety having at least one oxygen or nitrogen atom, and R may be an organic functionality, for example, an acetate or a p-toluene sulfonyl group. S may be aromatic, aliphatic, substituted, or unsubstituted. For example, S may comprise a furanyl, tetrahydrofuranyl, pyrrolidinyl, furoyl, pyrrolyl, or substituted derivatives of these. Exemplary substituents include NO[0022] 2, NH2, isothiocyanato, semicarbazido, thiosemicarbazido, maleimido, bromoacetomido, and carboxyl groups.
  • In another aspect, the invention is an apparatus for detection of a clearance rate of a substance from extracellular fluid. The apparatus comprises a light source capable of producing light having sufficient intensity and energy to be absorbed by an electroluminescent moiety in the subject's extracellular fluid, an optical fiber to deliver light from the light source to the subject, a detector, an optical fiber to deliver light emitted by the electroluminescent moiety to the detector, and processing means to calculate the rate of depletion of the electroluminescent moiety based on values measured by the detector. The light source may be a pulsed laser having a frequency such that it emits light at a time interval which is a predetermined fraction of a decay time of the electroluminescent moiety. [0023]
  • In another aspect, the invention is an electroluminescent molecule. The molecule comprises a polyaminopolyacetic acid derivative conjugated with an electroluminescent moiety and exhibits fluorescence when irradiated with red or infrared light. The molecule may be attached to an antibody, a DNA fragment, an RNA fragment, an enzyme, or an enzyme co-factor attached to the polyaminopolyacetic acid derivative. The molecule may also include an oligonucleotide. In another embodiment, the invention is a method of performing magnetic resonance imaging on a patient. The method comprises injecting the electroluminescent molecule into a patient, exposing the patient to a magnetic field, exposing the patient to a radio frequency pulse, and measuring the emission of hydrogen ions within the patient after removal of the pulse. [0024]
  • In another aspect, the invention is a method of performing immunochemical analysis. The method comprises associating a first electroluminescent complex with an analyte, exposing the first electroluminescent complex to light at an absorbance wavelength of the complex, and detecting light emitted by the first electroluminescent complex. The first complex comprises a bicyclic polyaminopolyacetic acid analog and an electroluminescent agent chelated to the bicyclic polyaminopolyacetic acid analog. The electroluminescent agent may comprise a lanthanide ion. The lanthanide ion may be trivalent and may comprise Ce[0025] +++, Nd+++, Sm+++, Eu+++, or Tb+++. The method may further comprise associating a second ligand labeled with a second electroluminescent complex with a second analyte, wherein the emission wavelength of the second complex is detectably different from the emission wavelength of the first complex. The method may be performed with more than two ligands and complexes. The electroluminescent complex may exhibit a decay time greater than 50 ns. The steps of exposing and detecting may be repeated. The method may further comprise attaching a first ligand to the analyte, wherein the first electroluminescent complex is associated with the analyte via attachment to the ligand; alternatively, the first electroluminescent complex may be attached to the first ligand via a second ligand. The analyte may be immobilized on a support, for example, via a ligand. Association may comprise removing an electroluminescent agent associated with the analyte and coordinating the electroluminescent agent with the bicyclic polyaminopolyacetic acid analog to form the first electroluminescent complex. In this embodiment, the bicyclic polyaminopolyacetic acid analog is not attached to the analyte, and the electroluminescent agent is attached to the analyte via a ligand. The bicyclic polyaminopolyacetic acid analog may be sequestered in a micelle. The ligand may comprise an antibody, a DNA fragment, an RNA fragment, an enzyme, or an enzyme co-factor. The polyaminopolyacetic acid derivative may comprise
    Figure US20030017111A1-20030123-C00002
  • S may be a cyclic organic moiety having at least one oxygen or nitrogen atom, and R may be an organic functionality, for example, an acetate or a p-toluene sulfonyl group. S may be aromatic, aliphatic, substituted, or unsubstituted. For example, S may comprise a furanyl, tetrahydrofuranyl, pyrrolidinyl, furoyl, pyrrolyl, or substituted derivatives of these. Exemplary substituents include NO[0026] 2, NH2, isothiocyanato, semicarbazido, thiosemicarbazido, maleimido, bromoacetomido, and carboxyl groups.
  • In another aspect, the invention is a molecule comprising [0027]
    Figure US20030017111A1-20030123-C00003
  • S may be a cyclic organic moiety having at least one oxygen or nitrogen atom, and R may be an organic functionality, for example, an acetate or a p-toluene sulfonyl group. S may be aromatic, aliphatic, substituted, or unsubstituted. For example, S may comprise a furanyl, tetrahydrofuranyl, pyrrolidinyl, furoyl, pyrrolyl, or substituted derivatives of these. Exemplary substituents include NO[0028] 2, NH2, isothiocyanato, semicarbazido, thiosemicarbazido, maleimido, bromoacetomido, and carboxyl groups.
  • BRIEF DESCRIPTION OF THE DRAWING
  • The invention is described with reference to the several figures of the drawing, in which, [0029]
  • FIG. 1 is a graph correlating the rate constant for clearance of [0030] 99mTc-DTPA and measured glomerular filtration rate (broken line: 95% confidence limit; n=50);
  • FIG. 2 is a graph illustrating the principle of time-delayed fluorometry; [0031]
  • FIG. 3 is a schematic of a laser-induced fluorescence instrument for use with the invention; [0032]
  • FIG. 4 is a graph showing the fluorescence excitation (continuous line) and emission (broken line) spectra of nile blue-DTPA; [0033]
  • FIG. 5 is a graph showing the fluorescence excitation (continuous line) and emission (broken line) spectra of Eu-EGTA; [0034]
  • FIG. 6 depicts a macrocyclic compound according to an embodiment of the present invention; [0035]
  • FIG. 7 depicts an exemplary synthetic pathway for production of TABFTA; [0036]
  • FIG. 8 displays exemplary starting materials, intermediates, and end products for use in the methods of the invention; [0037]
  • FIG. 9 illustrates the excitation and decay processes resulting in the advantageous emission properties of lanthanide atoms; [0038]
  • FIG. 10 illustrates a finger sleeve with which an apparatus according to the invention can be operated.[0039]
  • DETAILED DESCRIPTION
  • The present invention provides laser fluorescent dye derivatives and lanthanide chelates for real-time, transcutaneous fluorescence measurements of organ function, for example, glomerular filtration rate, renal blood flow, and hepatic function. To be considered suitable, the new fluorescent agent should have several additional characteristics besides the requirements described above. First, for optimal tissue penetration and minimal background interference, the excitation wavelength of a new agent should be greater than 600 nm. Preferably, the emission wavelength will be in the red or infrared to maximize tissue penetration. Second, the new agent should be very soluble and stable in aqueous solutions. Third, the agent should be non-toxic. [0040]
  • In comparison with the radioisotope method, the intrinsic sensitivity of fluorometric assay is extremely high (Mathies, R. and L. Stryer, [0041] Applications Of Fluorescence In The Biomedical Sciences, Taylor D. L., Murphy R. F., Canni F., Birge R. R., Eds. New York: Alan R. Liss, Inc., pp. 129-140, 1986). Unfortunately, the high sensitivity obtained in thoroughly in vitro controlled conditions are lost in less optimal in vivo surroundings as a result of background interference (Soini, E. and I. Hemmila, Clin. Chem., 25: 353-361, 1979). However, the intrinsic sensitivity of the fluorometric analysis should be restored in vivo by taking advantage of both the temporal and spectral resolutions of the technique, recommending fluorometry as a method for real-time renal monitoring without the disadvantages of radiotracers. The background level in fluorometric analysis is a sum of several factors, including scattering and the presence of other fluorescent compounds. Scattering from solvents, solutes, and particles results in background fluorescence in fluorometric measurements, especially when measuring fluorescent probes of short Stokes shift. In addition to scattering, sample constituents like protein, hemin, NADH, etc., cause background fluorescence extending from 300 nm to nearly 600 nm (Soini, 1979). Another important characteristic of this background fluorescence is that its average decay time is less than 50 ns (Mathies, 1986). Two different approaches can be used to reduce or eliminate background activity in the in vivo measurements. One is, as proposed before, to select fluorescent agents with an emission wavelength higher than 600 nm. The other is to use time-resolved fluorometry. Time-resolved fluorometry is a method by which the fluorescence emission is counted after a certain delay time following pulse excitation (Soini, 1979). With this system, background fluorescence can be eliminated, provided that the decay time of the specific signal is substantially longer than the average decay of the background (FIG. 2). FIG. 2 shows that after a pulse excitation A, the background radiation B decays rapidly, allowing detection of emission from Tb (C) and Eu (D), before a subsequent excitation A. If the decay time is long enough, several measurements can be made following excitation at time E1 before the fluorophore must be re-excited. As shown in FIG. 2, once the background fluorescence decays sufficiently (T1), measurements can be repeated between times T1 and Tn or Tn′, following which the fluorophore is re-excited. In addition, this technique also prevents quenching, a process in which fluorophores stop emitting when they are excited too long or too often. Time-resolved fluorometry enables both excitation times and frequencies to be reduced, enabling longer intervals during which renal function may be measured.
  • The utility of lanthanide chelates for time-delayed fluorometry stems from the unique luminescence properties of these complexes. While the luminescence of these molecules is commonly described as fluorescence, the relaxation mechanism of the excited atom is actually much more complex. As shown in FIG. 9, when a lanthanide chelate is irradiated, the ligand molecule absorbs enough energy to be excited to state S[0042] n. The ligand quickly relaxes to singlet excited state S1, a non-radiative process. Relaxation from this state to ground state G is properly termed fluorescence; however, the resulting emission would not be useful for time-resolved techniques. The ligand may also relax from the singlet state S1 to triplet state T via a non-radiative mechanism. Relaxation via emission from this state is called phosphorescence. This emission is relatively slow (on the order of milliseconds) in comparison to fluorescence (on the order of nanoseconds). However, if the energy is transferred to the metal ion (states d1 or d2); then the complex may relax to the ground state either directly from d1 or d2 or indirectly after relaxation from d2 to d1. As can be seen in FIG. 9, the emission wavelength for this process is much different than for the absorption wavelength. In addition, relaxation from state d2 or d1 is even slower than relaxation from the state T. Indeed, the fluorescence lifetime of a conventional fluorophore rarely exceeds 100 ns; the fluorescence lifetime of a lanthanide ion ranges between 100 s and 1000 s (Diamandis, E. P., Electrophoresis, 14: 866-875, 1993). The slow emission and large energy (and emission wavelength) difference between S1 and either d2 or d1 make time-resolved fluorometry a very powerful technique. The slow emission also facilitates real-time monitoring by maximizing the intervals during which measurements may be made and reducing the interruptions due to re-excitation of the fluorophore.
  • Feasibility Study: Before pursuing the rather complex and time consuming process that represents the synthesis and screening for a suitable fluorescent GFR agent, the feasibility of using transcutaneous fluorescence measurements (TFM) to measure the tissue concentration of the fluorescent agent was determined. The study was performed with a laser induced fluorescence system (Frisoli, J., E. Tudor, et al., [0043] Cancer Res., 53: 5854-5961, 1993). A basic layout of the system is shown in FIG. 3. A pulse-nitrogen laser (DLM VSL-337ND; Laser Science Inc. Cambridge, Mass.) was used to pump a Dye Laser 220 (Laser Science, Inc.) containing rhodamine 610 dye (Exciton Chemical Co., Dayton, Ohio). The 610 nm excitation pulses were launched into a 600 nm core diameter fused silica optical fiber (Superguide-G; Fiberguide Industries, Stirling, N.J.) with a 5 mm focal length. After coupling, reflection, and fiber losses, the typical pulse energy incident on the tissue was approximately 10 J. Fluorescence from the tissue was collected by a second 600 m fiber and separated by a constant distance (one fiber diameter plus cladding and jacket=800 m). The output of the collection fiber was optically coupled to a quartz fiber bundle having a circular arrangement of fibers at the input. The fibers at the output end of this bundle were arranged linearly and served as a 0.1 mm×2.5 mm entrance slit for a f/3.8, 0.275 m polychromator (Monospect 27; Anaspect, Acton, Mass.). A long pass filter (CS 2-59; Swift Glass Co., Elmira, N.Y.) was inserted before the quartz fiber bundle to eliminate scattered light. Fluorescence for wavelengths between 300 and 800 nm was recorded using an intensified 1024-diode array controlled by an optical multichannel analyzer (OMA III; Princeton Applied Research, Princeton, N.J.). The intensifier was gated with 100 ns pulses centered on the 3 ns laser pulse. A complete spectrum was recorded with each excitation pulse, and 50 spectra were averaged for each measurement. Although rather bulky, this laser-induced fluorescence (LIF) system has a versatility that is essential for the selection of the most appropriate excitation beam, optic filters, and detector system for the final design of FARM.
  • Drug uptake and clearance measurements were performed in 75-100 g male Syrian hamsters (Charles River Laboratories, Wilmington, Mass.) after the intravenous injection of 10 mg/kg body weight of chloroaluminum sulfonate phthalocyanine (CASPc). The fluorescence measurements were performed after the hamsters were made temporarily unconscious by immersion in a CO[0044] 2 atmosphere. The optical fibers were placed in gentle contact with the tissue (tongue) and a spectrum was acquired as described before. The fluorescence intensity at 684 nm was monitored as a function of time after injection of the dye. Some autofluorescence was excited by 610 nm light, but interference was minimal at 684 nm and was eliminated by subtracting the preinjection signal intensity for each hamster from all subsequent spectra. Absolute CASPc concentrations in the tissue were determined by alkaline chemical extraction in experiments utilizing a separate group of hamsters. The absolute amount of CASPc was determined by measuring the fluorescence spectrum of the supernatant in a 2 mm thick cuvette using the LIF instrument. Data were analyzed with a multicompartment pharmacokinetic model. The results showed that there was a positive linear correlation between the LIF intensity and CASPc concentration as determined after extraction of the dye. Moreover, the changes in CASPc concentration (obtained from the TFM) versus time followed the changes in CASPc tissue concentration very closely, as determined after extraction of the dye. These results demonstrate that is highly possible to determine changes in the tissue concentration of a fluorescent agent by measuring the transcutaneous fluorescent signal from this agent and that there is no significant interference from the different tissue components in this type of measurement. Moreover, these results demonstrate the utility of fluorescent techniques for real-time monitoring of renal function. Although CASPc is not a GFR agent, the dye was used as a temporary alternative to demonstrate the feasibility of using the transcutaneous fluorescence measurements to measure the tissue concentration of the fluorescent dye before pursuing the synthesis of the appropriate fluorescent GFR agent.
  • Fluorescent Agents: Two different procedures were used to obtain the new fluorescent agents. Both approaches employed an agent with clearance characteristics of an “ideal” GFR agent (for instance EDTA, DTPA, low molecular weight Dextran, or a polyazamacrocyclic molecule) as the primary reactant. Selecting a stable GFR agent as the basic starting reactant increases the likelihood that the final fluorescent product will retain most, if not all of the properties of the initial GFR agent. In one of the procedures, the fluorescence marker was a laser dye with a long emission wavelength, e.g. nile blue, oxazine 750, or indocyanine green, and, in the other, a trivalent lanthanide such as neodymium. [0045]
  • For the synthesis of a nile blue-DTPA conjugate, 0.1 g of DTPA dianhydride (ccDPTA) was dissolved in 6 ml of dimethyl sulfoxide (DMSO) in a round bottom flask. Ninety mg of nile blue were dissolved in DMSO and 36 L of triethyl amine were added, turning the solution purple. The nile blue solution was added drop wise to the solution of ccDTPA while stirring. The solution turned blue. Thirty-eight L of triethanolamine (TEA) were added to the final mixture, turning the solution purple. After mixing, the mixture was heated to 60° C. and stirred for 2 hours. The reaction mixture was then loaded onto a silica gel column and eluted with acetone:ethylacetate. The fractions corresponding to the nile blue-DTPA conjugate were pooled and evaporated, yielding a magenta colored oil. The oil was rechromatographed on a second silica gel column using acetone as eluant. The nile blue-DTPA conjugated fractions were pooled and rotate-evaporated to give a magenta colored oil. Silica thin layer chromatography (TLC) using ethylacetate:ethanol:TEA (40:40:1) indicated that the nile blue-DTPA conjugate migrated as a single spot with an Rf of 0.9 while the nile blue dye migrated with an Rf of 0.5. Fluorometric analysis (FIG. 4) indicated that the coupling of DTPA to the 5-amino group of nile blue produced a shift in the emission fluorescence from 695 nm to 530 nm, while the maximal excitation remained virtually unchanged at approximately 390 nm. The shift in emission wavelength results in a excessively small Stokes shift ([0046] emission−excitation) for the conjugate. Because of the overlap between the excitation and emission spectra, it is difficult to distinguish the two in real-time measurements. On the other hand, while lanthanide chelates can be produced using similar methods, the emission wavelength of the product is not significantly reduced in comparison with that of the free ion.
  • Because none of the laser dyes discussed above have sufficiently long decay times for use in time-delayed fluorometry, lanthanide chelates were also investigated. They are known to have a long decay-time for fluorescence, making them an optimal choice for time-resolved techniques. Trivalent lanthanide ions like Ce[0047] 3+, Nd3+, Sm3+, Eu3+, and Tb3+exhibit a special kind of fluorescence characterized by narrow-banded emission lines and long fluorescence decay times. One of the limitations of lanthanide ions, however, is that alone they produce a very weak fluorescence signal. To improve the fluorescence signal, the lanthanide ions need to be combined with an appropriate enhancer. When chelated with suitable light absorbing ligands, the ion fluorescence is enhanced by several orders of magnitude.
  • The best known and most widely used ligands to produce fluorescent lanthanide chelates are the -diketones, especially their fluorinated aromatic forms (Hemmila, I., S. Dakubu, et al., [0048] Anal. Biochem., 137: 335-343, 1984; Hemmila, I., Anal. Chem., 57: 1676-1681, 1985). Although europium could be measured with high sensitivity as a -diketone chelate, this approach has important limitations. First, since the fluorescent GFR agent is distributed in a aqueous media (extracellular space), the -diketone has to be solubilized with the use of a nonionic detergent (Hemmila, 1984). Second, the binding of the chelate's components is not strong enough to avoid spontaneous dissolution in water (Hemmila, 1984) and, as a result, loss of fluorescence and expression of possible toxic effects of the lanthanide and -diketone. All of these limitations can be circumvented by the use of an enhancer with strong chelating properties from which the lanthanide will dissociate very slowly, or not at all, under the required experimental conditions.
  • The only group of chelating agents known to produce highly soluble and stable lanthanide chelates are the polyamino polyacetic acid analogs. Although previous studies have shown that the chelate between the most commonly used members of this group (EDTA) and europium is essentially non-fluorescent (Hemmila, 1984), the fluorescence of the chelate can be greatly enhanced by modifications of the EDTA molecule (Yeh, S., D. Sherman, et al., [0049] Anal. Biochem., 100: 152-159, 1979). The simplest initial approach was to study the fluorescence characteristics of the chelate between Eu and other already commercially available polyaminopoly bis (2-aminoethyl ether) acetic acids. Ethylene glycol N,N,N′,N′-tetraacetic acid (EGTA) has two aminoethyl ether groups. As a result of this molecular structure, EGTA should show similar energy absorption and transfer properties to those found in the -diketones in addition to its strong metal chelating properties. As predicted, the chelate between europium and EGTA is fluorescent, eliminating the need for an additional enhancer. FIG. 5 also shows that the chelate maintains the narrow emission bands characteristic of Eu (590 nm and 613 nm).
  • One of the limitations of the EGTA lanthanide chelates, however, is that they are not as stable in aqueous solution as the polyazamacrocyclic lanthanide chelates are. For instance, the stability constant of EGTA-lanthanide complex is 10[0050] 17, while the stability constant of the polyazamacrocyclic DOTA-lanthanide chelates is several orders of magnitude higher (K=1020) (Bousquet, J., S. Saini, et al., iRadiology, 166: 693-698, 1988). Since there is a close correlation between in vitro stability and in vivo safety (Bousquet, 1988), the lower stability constant of EGTA-lanthanide chelates may create some concern about possible toxic effects due to the deposition of free lanthanide in bone and soft tissue. Despite the striking differences in the stability constant, however, use of EGTA chelates in fluorescence studies is safer than the use of DOTA chelates in MRI studies. The reason for this apparent discrepancy is that, due to the high intrinsic sensitivity of the fluorescent techniques, the fluorescent agents are used as tracers, not as contrast agents. The required concentration of fluorescent agents is several orders of magnitude smaller than the concentration of DOTA chelates used in MRI contrast studies. Despite a higher safety factor, however, the potential toxicity of EGTA-chelates, especially after repeated doses, remains a concern.
  • Chelating agents based upon tetraazamacrocyclic backbones have proven to be extremely valuable for generating aqueous stable lanthanide chelates. The superior nature of this class of chelates has made them useful for diagnostic and therapeutic medical applications. For example, paramagnetic chelates of these compounds based upon gadolinium (Gd) are currently used as contrast agents for magnetic resonance imaging (MRI). Unfortunately, the current tetraazamacrocyclic chelates of Gd used in MRI are either very weakly fluorescent or exhibit no fluorescence at all. However, the addition of an aromatic moiety to the chelate can enhance luminescence. For example, a newly developed polyazamacrocyclic chelate incorporating a pyridine as the enhancer group exhibited fluorescence emission with a large difference between the excitation and emission wavelengths (>280 nm) and a high quantum yield of 0.51 (Costa, J. and R. Delgado, [0051] Inorg. Chem., 32: 5257-5265, 1993; Kim, D., G. Kiefer, et al., Inorg. Chem., 34: 2233-2243, 1995; Bornhop, D., D. Hubbard, et al., Anal. Chem., 71: 2607-2615, 1999). Unfortunately, the flexibility of the macrocycle following the introduction of the pyridine moiety was partially lost while the orientation of the ester arms was affected by the asymmetry in the macrocycle. As a result, the affinity constant was even lower (k=19.5) than the value for DTPA (k=23) (Aime, S., M. Botta, et al., J. Chem. Soc., Chem. Commun., 1995:1885-1886, 1995). In addition, incorporation of the pyridine group, in conjunction with the substitution of the acetate groups for phosphonic acid n-butyl ester groups, resulted in an increase in the lipid solubility of the compound. As a result, the new molecule exhibits significant hepatic and bowel excretion in addition to renal excretion (Bornhop, 1999). The pharmacodynamic characteristics of this compound render it totally unsuitable for the present application. In contrast, for the instant invention, the starting reactants in the synthesis of the new agents are compounds with a well-recognized organ and function specificity.
  • To increase chelate stability while retaining the advantages of the lanthanide chelates, a new GFR agent is proposed. The new fluorescent agent is based on lanthanide chelates derived from the polyazamacrocyclic compound of general formula ([0052] 5), wherein the second cyclic group (S) is part of the macrocyclic backbone (FIG. 6). The second cyclic group (S) may be a furan, a tetrahydrofuran, a pyrrole, a pyrrolidine, or a derivative such as 3-furoic acid. Chelates derived from this family of macrocyclic ligands are among the most thermodynamically and kinetically stable lanthanide complexes, an important consideration for human studies where metal ion toxicity is a major concern. The compound of formula 25, tetraazabycyclofurantetraacetate (TABFTA) is very similar to the compound tetraazacyclododecane tetraacetic acid (DOTA) used as an MRI contrast agent (FIG. 7). As a result, it is anticipated that after intravenous injection, the chelates of TABFTA and a lanthanide such as neodymium will have biological characteristics similar to the chelates of DOTA and gadolinium, such as being excreted only by glomerular filtration and having an extracellular space distribution (Bousquet, 1988). In this concern, measurement of renal function and, in particular, glomerular filtration will be pursued without further structural modifications of TABFTA.
  • To take advantage of the low background interference of time-resolved fluorometry, TABFTA can also be used also as a bifunctional chelating agent for the labeling of antibodies, antibody fragments, hormones, hormone fragments, nucleic acids, neurotransmitters, or any other biologically active material. For example, TABFTA may be modified as depicted in formula [0053] 45 by introduction of a NO2, NH2, isothiocyanato, semicarbazido, thiosemicarbazido, maleimido, bromoacetomido or carboxyl group in position 15 (FIG. 8).
  • Synthesis of chelate: The complexes are prepared by methods well known in the art (Dwyer and Mellor, [0054] Chelating Agents and Metal Chelates, Academic Press, 1964; Richman, J. and T. Atkins, J. Am. Chem. Soc., 96: 2268-2270, 1974). All the reactants are commercially available. FIG. 7 provides a detailed description of the preparation of one of the compounds of this invention, a 15-member tetraazamacrocyclic structure possessing one dimethylfuran moiety. 2,5-dimethylfuran (10) is first converted to the chloromethyl derivative (15). In a separate step, triethylenetetraamine is tosylated and converted to the sodium salt. These two reagents are then combined in DMF to give the N-tosylated macrocycle (20) (Richman, 1974). Heating the product in a mixture of acetic acid (AcOH) and HBr provides a protecting group to the amine groups. The tetraacetic derivative (25) is then synthesized by reacting the secondary amines of the macrocycle with chloroacetic acid as described by Desreux (Desreux, J., Inorg. Chem., 19: 1319-1324, 1980).
  • The second cyclic group S may be varied to modify the electron density of the molecule and the electron distribution along the backbone. For example, compound [0055] 10 can be replaced with 2,5-dimethyltetrahydrofuran (30), 2,5-dimethylpyrrolidine (33), 2,5-dimethyl-3-furoic acid (35), or 2,5-dimethylpyrrole (40). Use of compound 15 results in production of compound 50 instead of compound 20 as an intermediate. One skilled in the art will see that a number of different substituents, such as the isothiocyanate group in compound 45, can be placed on the molecule by an appropriate choice of precursor for cyclic group S.
  • Treatment of these compounds with a lanthanide acetate yields the desired fluorescent chelate. Neodymium, terbium or europium acetate (0.1M) and an equimolar amount of tetraazacycloalkene N, N′, N″, N″″ derivative are mixed in water at 80° C. The pH of the solution is adjusted to 10 by addition of concentrated NH[0056] 4OH and the mixture stirred for 20 h. After filtration, the cooled reaction solution is evaporated to a solid and dried overnight in a vacuum oven to sublime the byproduct, ammonium acetate.
  • Detection: All the components for the assembly of an instrument for TFM are commercially available and have been tested extensively in everyday applications. The essential components of the instrument are the following: [0057]
  • a) the fluorescence excitation system; [0058]
  • b) the fluorescence detection system; and [0059]
  • c) the operating system and data logger. [0060]
  • a. The fluorescence excitation system: The excitation system may incorporate either high intensity light-emitting photo diodes or laser diodes. These components have several properties that make them ideal for the present application by increasing safety and portability. They are current sensitive devices with low-power output, low operating voltage, and high-frequency response. Both types of diodes are very small and can be battery-operated with input power of 3.5 to 5.0 VDC and only 50-100 mA input currents. [0061]
  • For standard fluorometry, a better match between the dye excitation wavelength and the component emission wavelength can be obtained with the high intensity light-emitting photo diodes than with laser diodes. High intensity, light-emitting photo diodes offer a broad selection of wavelengths from which a specific wavelength can be selected to better match the excitation wavelength of the fluorescent dye. For time-resolved fluorometry with neodymium chelates, however, laser diodes with an emission wavelength of 830 nm are preferred because their emission wavelength is a perfect match for the excitation wavelength of the lanthanide. [0062]
  • Both light sources have the advantage of very high frequency response. Thus, the emitted light beam can be pulsed with a regulated electronic pulse generator by turning the source on and off. This electronic gating system offers several advantages over the mechanical system, including better control of the frequency, duration, and intensity of the light pulses. For GFR agents labeled with laser dyes, the emitted light intensity measurements are performed during pulses; for lanthanide chelates, the measurements are performed between pulses, after the background fluorescence has decayed to minimal values. [0063]
  • Separation of the excitation from the emission beam is accomplished by using long wave pass filters, whose small size and weight increase portability. A diagram of the system is displayed in FIG. 3. Filters with an appropriate cut-on wavelength are selected for the specific fluorescent agent in use, e.g., 850±7 nm (for neodymium-chelates) or 700±6 nm (for indocyanine green-EDTA or oxazin-EDTA). The 850 nm filter should reflect and re-direct a 830 nm beam from the laser source to the tissue while allowing full transmission of the 1,050 nm and 1,350 nm emission bands of neodymium-chelates. Similarly, the 700 nm filter should reflect and re-direct the 420-600 nm beam from the high intensity light-emitting photo diodes to the tissue while allowing full transmission from the tissue to the detector unit of the emission beam of the indocyanine green-EDTA or oxazin-EDTA. The excitation pulses are launched into single or multiple 2000 m core-diameter fused silica optical fibers or liquid core lightguides with a 5 mm focal length lens. After a proximal short circular arrangement, the fibers are rearranged linearly to obtain a structure similar to a short band [0064] 55 (FIG. 10). This excitation band is placed and secured over the skin or mucosa of a body part, for example, finger 60, to excite the tissue underneath. The volume of the excited tissue is changed by adjusting the intensity of the excitation beam or the number and/or core diameter of the liquid lightguides or silica optical fibers 65.
  • A serious concern with the present technology is that the use of laser beams may result in tissue damage. However, this possibility can be eliminated or at least minimized by incorporating four important features into the design of the instrument. First, excitation is accomplished with the use of laser diodes with very low power output (i.e., 2-5 mW) to avoid exceeding an exposure rate of 0.003 J/cm[0065] 2. Second, the excitation beam is pulsed with an electronic pulse-generator to excite the tissue with very short laser pulses of only a few nanoseconds duration. Third, the wavelength of the excitation beam is always maintained over 420 nm. Finally, conduction of the excitation beam is performed with large core fiber optic bundle to distribute the excitation laser beam over a large area. The low power and short pulses of the excitation beam should also reduce the possibility of photobleaching frequently observed with the use of standard fluorescent dyes.
  • b. The detection system: Fluorescence from the skin or mucosa and deeper tissues will be collected by the excitation band and conducted through liquid lightguides or silica optical fiber to the long wave pass filter. The filter facilitates separation of the emission and excitation beams and reduces background contribution, as disclosed above. Fluorescence transmitted through the filter is recorded using an intensified photodiode array or IR detector for variable integration times. The intensifier/detector unit is electronically gated to measure the fluorescence intensity emitted during (for standard fluorometry) or a time after (for time resolved fluorometry) the excitation pulse. [0066]
  • c. The operating system and data logger: Tattletale® data loggers designed by Onset Computer are used to operate the system and record fluorescence vs. time. Several characteristics of this data logger make it ideal for the present application. The data file size for this series ranges between 8 to 224 Kb, more than sufficient to allow the instrument to perform all its expected functions. All the models available are battery-operated, low power system with drains between 2 to 3 mA. In addition, all the Onset Computer's Tattletale® loggers are pocket-sized, lightweight, sturdy units. The data logger, along with the batteries necessary to operate the system and the detector, are housed in a pocket-sized plastic box. The loggers are assembled with an alphanumeric display to show the updated rate constant value at pre-set intervals. This feature is extremely useful in acute situations such as operating rooms and intensive care units. The data loggers also have sufficient memory to determine the instant value of this constant for a long period of data collection. [0067]
  • Operation: The excitation/detector unit of the instrument is affixed to the skin covering a body part such as a fingertip or a section of the arm or to the nasal or oral mucosa of the patient. Organ function is then measured in real time as rate of depletion in tissue of a fluorescent agent that is cleared exclusively by that particular organ. In other terms, organ function is measured as the efficiency with which a particular organ removes a function-specific fluorescent agent from the tissue. The rate of depletion of the agent is measured from the change in the individual transcutaneous fluorescence measurements over time. The individual transcutaneous tissue fluorescence measurements are performed by integrating the emitted tissue fluorescence for a very short period of time (50 nsec to 100 msec) during (standard fluorometry) or after (time-resolved fluorometry) the excitation pulse. Since the excitation pulses are very short, the individual fluorescence measurements may be performed very frequently with minimal interruption between measurements. The rate of excretion is then determined by plotting the individual transcutaneous fluorescence measurements with respect to time for very short time intervals (2 to 5 minute intervals) after a bolus intravenous injection of the tracer. Since the system response follows first-order kinetics (Rabito, 1994), the slope of the correlation between the log of the individual fluorescence intensity measurements vs. time represents the rate constant of the system. The data collected is subjected to repetitive, on-line, least squares analysis to obtain the best fit between the log of fluorescence intensity (in arbitrary units) versus time (in minutes) at intervals of 2 to 5 minutes. After arrival, the new data is processed and added to the correlation to obtain a continuous update of the line. Analysis of co-variance (ANOVA) is used to assess the differences between the slope (rate constant) for the previous and the current 2 to 5 minute intervals. Thus, a rate constant and its corresponding statistical value can be generated almost continuously. Decreases or increases in the rate constant value are considered to represent decreases or increases in GFR when the patient is injected with a fluorescent GFR agent. [0068]
  • Although current data loggers have the computer power necessary to determine the value of this constant on the instrument, the data can also be transferred to a dedicated personal computer. After transferring the data, the required curve fitting and complete analysis is carried out by using a commercially available statistics software package. [0069]
  • Software: The basic software for the operation of the unit is a modification of the program developed initially for the renal monitor that works with radioactive tracer (Rabito, 1994). The program is designed to control the type of excitation to be used (continuous or pulse excitation), duration of the excitation pulse, interval between pulses, the time between the excitation pulse and the measurement of the emission signal, and the integration period for the measurement of the emission signal. For standard fluorescence determination, the emitted fluorescence intensity is measured during each pulse. For time-resolved fluorescence measurements, however, the operating program is set to integrate the emission signal a few microseconds after the laser pulse to allow for full background decay. The analysis software is based on the single compartment model described by Brochner-Mortensen (Brochner-Mortensen, J., [0070] Scand. J. Clin. Lab. Invest., 30: 271-276, 1974) as was previously published (Rabito, 1994).
  • Conclusions-Real-Time Renal Monitoring: FARM has several definite advantages over the radioactive monitoring technique described in the Background. First, the technique will eliminate the use of radioactivity with all its intrinsic limitations. Second, FARM can be assembled with more standard components than the radioactivity detectors. For instance, the laser diodes and laser detectors are very inexpensive ($50 to $125) and widely available laser components that have been tested extensively in everyday applications such as CD players, printers, facsimile machines, laser security fences, etc. On the contrary, the cadmium-telluride detectors for monitoring radioactive tracers are available from only two manufacturers in the USA, at a cost that is about 15 times higher ($2,500) than the laser components. Another advantage of FARM is that, as a result of a simpler design, the patient will be more comfortable wearing the instrument for extended periods of time. For example, the excitation/detection system of FARM can be arranged in a finger sleeve which is more comfortable and less bulky than the heavy lead-lined arm sheaths used in the radioactivty assay. FARM can also be used for multi-label assays in which different fluorophores having different emission wavelengths are used simultaneously. [0071]
  • In FARM, the fluorescent signal originates solely in the tissue volume excited by the laser beam (Frisoli, 1993), eliminating the scattered activity from adjacent body structures commonly found with the radioactive method and obviating the need for special shielding. This attribute should result in a significant decrease in the total weight of FARM and more comfort for the patient, especially during prolonged monitoring of renal function. Two other important advantages of FARM over the radioactive technique are that the tissue volume probed during measurement remains relatively constant, and that the size of this volume can be adjusted by changing the excitation wavelength. This feature permits adjustment of the sensitivity of the instrument to a particular need without changing the dose of the fluorescent agent injected. [0072]
  • In conclusion, FARM, especially when conducted with the novel molecules disclosed herein, provides a reliable method for real-time monitoring of renal function. This technique, in conjunction with appropriate agents, may be exploited to monitor metabolic function for other organs as well. It provides a powerful tool for health care providers to quickly identify patients experiencing kidney or other organ failure and apply appropriate remedies. [0073]
  • Immunoassay: The molecules of the invention can also be used as labels for bioanalytical assays. The molecules can be attached to specific binding reagents, or ligands, for a variety of analytes. For example, they can be attached to antibodies for use in immunoassays, DNA or RNA fragments for hybridization assays, or enzyme or enzyme cofactors for enzyme assays. The molecules may be directly attached to the specific binding agent for the analyte or may be attached to a more general binding agent that acts as a secondary label. In the latter case, the secondary agent binds to a primary specific reagent. In another embodiment, the analyte may be immobilized on a substrate, following which the specific binding agent labeled with the luminescent molecule is allowed to bind to the analyte. The labeled agent may be attached to the analyte and excess unbound agent washed away. At this point, the molecule may be separated from the specific binding agent. The concentration of the molecule will still reflect the quantity of analyte; however, the concentration of the molecule can be measured in solution instead of an immobilized solid phase. [0074]
  • Alternatively, the metal ion may be chelated to a non-luminescent label attached to the specific binding agent. After the excess agent is rinsed away, only the metal atom is detached, for example, by changing the pH of the solution. The metal ion is then solubilized into a micelle carrying the organic chelate which binds a metal ion to form a luminescent complex. Suitable micellar materials include Triton X-100 (CAS 9002-93-1, available from Sigma-Aldrich, Inc.) detergent in phosphate buffer. Once the metal ion is separated from the labeling chelate, for example, EDTA or DTPA, it is incorporated into the micelle. Because unchelated lanthanides do not emit particularly intensely, the micelles also contain a chelating agent such as the molecules of the instant invention. This method has been commercialized using Eu as the metal ion and -naphthoyltrifluoracetone (NTA) and trioctylphosphine oxide (TOPO) as the chelate. Multiple antigens can be detected simultaneously by using different ions to label each. [0075]
  • All of these detection methods are well known in the art and are described, for example, in the review article by Dickson, et al. (Dickson, E. F. G., A. Pollak, et al., [0076] J. Photochem. Photobio. B, 27: 3-19, 1995). However, currently available fluorescent labels incorporating lanthanide ions suffer from low luminescence yield, low chelate stability, and low solubility in aqueous media. The lanthanide chelates disclosed herein were originally optimized for detection in blood, an aqueous medium, and are suitable for detection in other aqueous solutions. They also offer high affinity constants and luminescence yields (quantum efficiency=0.2-0.5).
  • Magnetic Resonance Imaging Contrast Agent: The molecules of the invention, especially TABFTA and its derivatives, can also be used as contrast agents for magnetic resonance imaging (MRI). When chelated with lanthanide ions such as gadolinium (Gd[0077] 3+) or technetium (Tc2+), the resulting paramagnetic compound enhances the relaxation of hydrogen protons, increasing signal intensities in MRI imaging (Bousquet, 1988). The increased signal increases the signal-to-noise ratio, reducing imaging time. In addition, the contrast agent may increase specificity in diagnosis. Because TABFTA is water-soluble, the complex can be used as a contrast agent in blood, for example, to measure blood flow in patients at risk for stroke or other circulatory malfunctions. Of course, the agent can also be used to image the functioning of the kidneys and bladder.
  • The performance of MRI on a patient is well understood by those skilled in the art. A patient is exposed to a high powered magnetic field, following which a radio frequency pulse is applied and absorbed by a small portion of the patient's hydrogen ions. The pulse changes the spin state of the protons; once the RF pulse is removed, the protons relax to their original spin state, releasing stored energy, which can be detected by the MRI apparatus. The contract agent is injected into the patient before exposure to the magnetic field. As noted above, the agent improves the performance of the apparatus. [0078]
  • Other embodiments of the invention will be apparent to those skilled in the art from a consideration of the specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims.[0079]

Claims (13)

    What is claimed is:
  1. 1. A molecule, comprising:
    a polyaminopolyacetic acid derivative; and
    an electroluminescent moiety chelated to the polyaminopolyacetic acid derivative, wherein the conjugate exhibits fluorescence when irradiated with red or infrared light.
  2. 2. The molecule of claim 1, wherein the moiety is a lanthanide ion.
  3. 3. The molecule of claim 2, wherein the lanthanide ion is trivalent.
  4. 4. The molecule of claim 3, wherein the lanthanide ion is selected from the group consisting of Ce3+, Nd3+, Sm3+, Eu3+, and Tb3+.
  5. 5. The molecule of claim 1, wherein the polyaminopolyacetic acid derivative is selected from the group consisting of diethylenetriaminepentaacetic acid (DTPA), ethylene glycol N, N, N′, N′-tetraacetic acid (EGTA), and polyaminopolybis(2-aminoethyl ether) acetic acid.
  6. 6. The molecule of claim 1, wherein the polyaminopolyacetic acid derivative comprises
    Figure US20030017111A1-20030123-C00004
    wherein S is a cyclic organic moiety having at least one atom selected from oxygen and nitrogen, and wherein R is an organic functionality.
  7. 7. The molecule of claim 6, wherein S is characterized by a member from the group consisting of aromatic, aliphatic, substituted, unsubstituted, and any combination of the above.
  8. 8. The molecule of claim 7, wherein S comprises a member of furanyl, tetrahydrofuranyl, pyrrolidinyl, furoyl, pyrrolyl, and substituted derivatives of the above.
  9. 9. The molecule of claim 7, wherein S is substituted with a member of NO2, NH2, isothiocyanato, semicarbazido, thiosemicarbazido, maleimido, bromoacetomido, and carboxyl group.
  10. 10. The molecule of claim 6, wherein R is an acetate or a p-toluene sulfonyl group.
  11. 11. The molecule of claim 1, wherein the conjugate exhibits a decay time for electroluminescence greater than 50 ns.
  12. 12. The molecule of claim 1, further comprising a member of the group consisting of an antibody, a DNA fragment, an RNA fragment, an enzyme, or an enzyme co-factor attached to the polyaminopolyacetic acid derivative.
  13. 13. The molecule of claim 1, further comprising an oligonucleotide.
US10228807 2000-07-19 2002-08-26 Fluorescent agents for real-time measurement of organ function Abandoned US20030017111A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US21936200 true 2000-07-19 2000-07-19
US09631138 US6440389B1 (en) 2000-07-19 2000-08-02 Fluorescent agents for real-time measurement of organ function
US10228807 US20030017111A1 (en) 2000-07-19 2002-08-26 Fluorescent agents for real-time measurement of organ function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10228807 US20030017111A1 (en) 2000-07-19 2002-08-26 Fluorescent agents for real-time measurement of organ function

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09631138 Division US6440389B1 (en) 2000-07-19 2000-08-02 Fluorescent agents for real-time measurement of organ function

Publications (1)

Publication Number Publication Date
US20030017111A1 true true US20030017111A1 (en) 2003-01-23

Family

ID=26913816

Family Applications (2)

Application Number Title Priority Date Filing Date
US09631138 Expired - Fee Related US6440389B1 (en) 2000-07-19 2000-08-02 Fluorescent agents for real-time measurement of organ function
US10228807 Abandoned US20030017111A1 (en) 2000-07-19 2002-08-26 Fluorescent agents for real-time measurement of organ function

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09631138 Expired - Fee Related US6440389B1 (en) 2000-07-19 2000-08-02 Fluorescent agents for real-time measurement of organ function

Country Status (5)

Country Link
US (2) US6440389B1 (en)
EP (1) EP1427451A2 (en)
JP (1) JP2004517041A (en)
CA (1) CA2418206A1 (en)
WO (1) WO2002005858A3 (en)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116958A1 (en) * 2001-02-06 2004-06-17 Achim Gopferich Spacing device for releasing active substances in the paranasal sinus
US20060063973A1 (en) * 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
WO2006037837A1 (en) * 2004-10-01 2006-04-13 Turun Yliopisto Dye particle and its preparation and use
US20070073269A1 (en) * 2005-09-23 2007-03-29 Becker Bruce B Multi-conduit balloon catheter
US20070129751A1 (en) * 2004-04-21 2007-06-07 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US20070179518A1 (en) * 2006-02-02 2007-08-02 Becker Bruce B Balloon Catheters and Methods for Treating Paranasal Sinuses
US20070208301A1 (en) * 2005-06-10 2007-09-06 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US20070208252A1 (en) * 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US20070249896A1 (en) * 2004-04-21 2007-10-25 Eric Goldfarb Endoscopic methods and devices for transnasal procedures
US20070282305A1 (en) * 2004-04-21 2007-12-06 Eric Goldfarb Endoscopic methods and devices for transnasal procedures
US20080015448A1 (en) * 2006-06-22 2008-01-17 Keely Patricia J Stromal collagen in the diagnosis and characterization of breast cancer
US20080097514A1 (en) * 2004-04-21 2008-04-24 Acclarent, Inc. Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat
US20080125720A1 (en) * 2006-05-17 2008-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US20080212867A1 (en) * 2007-03-02 2008-09-04 Provenzano Paolo P Use of Endogenous Fluorescence to Identify Invading Metastatic Breast Tumor Cells
US20080269643A1 (en) * 2007-04-30 2008-10-30 John Morriss Methods and devices for ostium measurement
US20080275483A1 (en) * 2004-04-21 2008-11-06 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear Nose and Throat
US20080319424A1 (en) * 2004-04-21 2008-12-25 Acclarent, Inc. Devices and Methods for Delivering Therapeutic Substances for the Treatment of Sinusitis and Other Disorders
US20090030409A1 (en) * 2007-07-27 2009-01-29 Eric Goldfarb Methods and devices for facilitating visualization in a surgical environment
US20090028923A1 (en) * 2005-01-18 2009-01-29 Acclarent, Inc. Implantable Devices and Methods for Treating Sinusitis and Other Disorders
US20090187098A1 (en) * 2004-04-21 2009-07-23 Acclarent, Inc. Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose, and/or Throat
US20090198216A1 (en) * 2004-04-21 2009-08-06 Acclarent, Inc. Frontal sinus spacer
US20090240237A1 (en) * 2006-09-15 2009-09-24 Acclarent Inc. Methods and Devices for Facilitating Visualization In a Surgical Environment
US20090312745A1 (en) * 2004-04-21 2009-12-17 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US20100099946A1 (en) * 2004-04-21 2010-04-22 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US20100114066A1 (en) * 2004-08-04 2010-05-06 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US20100174308A1 (en) * 2004-04-21 2010-07-08 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US20100305697A1 (en) * 2009-03-31 2010-12-02 Acclarent, Inc. System and Method For Treatment of Non-Ventilating Middle Ear by Providing a Gas Pathway Through the Nasopharynx
US20110160740A1 (en) * 2009-12-28 2011-06-30 Acclarent, Inc. Tissue Removal in The Paranasal Sinus and Nasal Cavity
US8100933B2 (en) 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
WO2013123285A1 (en) * 2012-02-17 2013-08-22 Pharmacophotonics, Inc. Compositions and methods for monitoring biometric indicators
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100784120B1 (en) * 2000-06-02 2007-12-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 EthylenedicysteineEC-drug conjugates
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20030215391A1 (en) * 2001-07-19 2003-11-20 Carlos Rabito Fluorescent agents for real-time measurement of organ function
GB0214340D0 (en) * 2002-06-21 2002-07-31 Multipex Photonics Ltd Apparatus for characterising a sample by an optical pulse
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
WO2006026038A1 (en) * 2004-08-26 2006-03-09 Mallinckrodt Inc. Luminescent metal complexes for monitoring renal function
US8664392B2 (en) 2004-12-23 2014-03-04 Medibeacon, LLC Pyrazine derivatives for bioconjugation
US8778309B2 (en) 2004-12-23 2014-07-15 Medibeacon Llc Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
EP2038261A2 (en) * 2006-06-22 2009-03-25 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
ES2456042T3 (en) 2006-06-22 2014-04-21 Medibeacon, LLC Pyrazine derivatives and uses thereof in renal monitoring
US20080107598A1 (en) * 2006-10-05 2008-05-08 Yang David J Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications
US20080085562A1 (en) * 2006-10-10 2008-04-10 Idexx Laboratories, Inc. Detection of gadolinium chelates
US20080085563A1 (en) * 2006-10-10 2008-04-10 Idexx Laboratories, Inc. Detection of Gadolinium Chelates
US7996068B2 (en) * 2007-03-14 2011-08-09 The Board Of Trustees Of The Leland Stanford Junior University Surgical method and apparatus for identification of fluorescence
CA2747454A1 (en) 2008-12-17 2010-07-08 Mallinckrodt Inc. Modified pyrazine derivatives and uses thereof
WO2014185372A1 (en) * 2013-05-13 2014-11-20 株式会社アライ・メッドフォトン研究所 Therapy-progress-level monitoring device and method
JP2017502706A (en) * 2013-10-22 2017-01-26 ハインリッヒ,ラルフ Improved transdermal organ function measurement

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243880A (en) * 1977-01-19 1981-01-06 Lkb-Produkter Ab Method for measuring time determination in a radiation measuring instrument
US4374120A (en) * 1979-03-08 1983-02-15 Wallac Oy Fluorescence spectroscopy assay means with fluorescent chelate of a lanthanide
US4428744A (en) * 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US4808541A (en) * 1983-03-15 1989-02-28 Lkb Produkter Ab Determination method utilizing reagents covalently labelled with essentially non-fluorescent lanthanide chelates in combination with time-resolved fluorescence spectroscopy and the reagents to be used in the method
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US4968631A (en) * 1986-01-30 1990-11-06 Golight, Inc. Method for detecting amines and aldehydes using lanthanide chelate fluorophores based on dihydropyridine condensation products
US4976950A (en) * 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US5021236A (en) * 1981-07-24 1991-06-04 Schering Aktiengesellschaft Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules
US5301673A (en) * 1991-11-18 1994-04-12 Massachusetts General Hospital Ambulatory clearance function monitor
US5316909A (en) * 1991-03-15 1994-05-31 Wallac Oy Method for increasing fluorescence
US5403572A (en) * 1988-07-20 1995-04-04 Schering Aktiengesellschaft Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them
US5468467A (en) * 1993-04-23 1995-11-21 Bracco International B.V. Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5656433A (en) * 1994-06-29 1997-08-12 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
US5660991A (en) * 1994-10-28 1997-08-26 Lakowicz; Joseph R. Long lifetime anisotropy (polarization) probes for clinical chemistry, immunoassays, affinity assays and biomedical research
US5811526A (en) * 1986-01-23 1998-09-22 Alusuisse Holdings A.G. Binding assay and assay reagent
US5928627A (en) * 1996-04-19 1999-07-27 The Dow Chemical Company Fluorescent chelates as visual tissue specific imaging agents
US5928625A (en) * 1997-03-13 1999-07-27 Mallinckrodt Inc. Method of measuring physiological function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587223A (en) 1982-09-13 1986-05-06 Wallac Oy Method for quantitative determination of a biospecific affinity reaction
DK0570575T3 (en) 1991-12-10 1998-08-24 Dow Chemical Co Bicykloazamakrocyklophosphonsyre, complexes, conjugates, contrast agents and their manufacture
EP1095011A4 (en) * 1998-07-07 2003-01-08 Smithkline Beecham Corp Novel fluorescent lanthanide chelates
DE19947559A1 (en) * 1999-09-24 2001-04-19 Schering Ag Antibody-dye conjugates against targets of angiogenesis for intraoperative tumor boundary representation

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243880A (en) * 1977-01-19 1981-01-06 Lkb-Produkter Ab Method for measuring time determination in a radiation measuring instrument
US4374120A (en) * 1979-03-08 1983-02-15 Wallac Oy Fluorescence spectroscopy assay means with fluorescent chelate of a lanthanide
US4428744A (en) * 1979-12-11 1984-01-31 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US5595725A (en) * 1981-07-24 1997-01-21 Schering Aktiengesellschaft Diagnostic media
US5021236A (en) * 1981-07-24 1991-06-04 Schering Aktiengesellschaft Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules
US4808541A (en) * 1983-03-15 1989-02-28 Lkb Produkter Ab Determination method utilizing reagents covalently labelled with essentially non-fluorescent lanthanide chelates in combination with time-resolved fluorescence spectroscopy and the reagents to be used in the method
US5811526A (en) * 1986-01-23 1998-09-22 Alusuisse Holdings A.G. Binding assay and assay reagent
US4968631A (en) * 1986-01-30 1990-11-06 Golight, Inc. Method for detecting amines and aldehydes using lanthanide chelate fluorophores based on dihydropyridine condensation products
US5403572A (en) * 1988-07-20 1995-04-04 Schering Aktiengesellschaft Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them
US4976950A (en) * 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5316909A (en) * 1991-03-15 1994-05-31 Wallac Oy Method for increasing fluorescence
US5301673A (en) * 1991-11-18 1994-04-12 Massachusetts General Hospital Ambulatory clearance function monitor
US5647363A (en) * 1991-11-18 1997-07-15 The General Hospital Corporation Ambulatory clearance function monitor
US5468467A (en) * 1993-04-23 1995-11-21 Bracco International B.V. Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
US5603917A (en) * 1993-04-23 1997-02-18 Bracco International B. V. Methods for the in vivo measurement of the concentration of NMR-detectable xenobiotic compounds
US5656433A (en) * 1994-06-29 1997-08-12 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
US5660991A (en) * 1994-10-28 1997-08-26 Lakowicz; Joseph R. Long lifetime anisotropy (polarization) probes for clinical chemistry, immunoassays, affinity assays and biomedical research
US5928627A (en) * 1996-04-19 1999-07-27 The Dow Chemical Company Fluorescent chelates as visual tissue specific imaging agents
US5928625A (en) * 1997-03-13 1999-07-27 Mallinckrodt Inc. Method of measuring physiological function

Cited By (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US20040116958A1 (en) * 2001-02-06 2004-06-17 Achim Gopferich Spacing device for releasing active substances in the paranasal sinus
US9457175B2 (en) 2002-09-30 2016-10-04 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8764786B2 (en) 2002-09-30 2014-07-01 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8100933B2 (en) 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US20070208252A1 (en) * 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US20070249896A1 (en) * 2004-04-21 2007-10-25 Eric Goldfarb Endoscopic methods and devices for transnasal procedures
US20070282305A1 (en) * 2004-04-21 2007-12-06 Eric Goldfarb Endoscopic methods and devices for transnasal procedures
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20080097514A1 (en) * 2004-04-21 2008-04-24 Acclarent, Inc. Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat
US20080103521A1 (en) * 2004-04-21 2008-05-01 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear Nose and Throat
US20080119693A1 (en) * 2004-04-21 2008-05-22 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear, Nose and Throat
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9610428B2 (en) 2004-04-21 2017-04-04 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US20080234720A1 (en) * 2004-04-21 2008-09-25 Acclarent, Inc. Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US20080275483A1 (en) * 2004-04-21 2008-11-06 Acclarent, Inc. Methods and Apparatus for Treating Disorders of the Ear Nose and Throat
US9370649B2 (en) 2004-04-21 2016-06-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US20080319424A1 (en) * 2004-04-21 2008-12-25 Acclarent, Inc. Devices and Methods for Delivering Therapeutic Substances for the Treatment of Sinusitis and Other Disorders
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9241834B2 (en) 2004-04-21 2016-01-26 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9220879B2 (en) 2004-04-21 2015-12-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US20090187098A1 (en) * 2004-04-21 2009-07-23 Acclarent, Inc. Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose, and/or Throat
US20070129751A1 (en) * 2004-04-21 2007-06-07 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9167961B2 (en) 2004-04-21 2015-10-27 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20090312745A1 (en) * 2004-04-21 2009-12-17 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US20100099946A1 (en) * 2004-04-21 2010-04-22 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20100121308A1 (en) * 2004-04-21 2010-05-13 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US20090198216A1 (en) * 2004-04-21 2009-08-06 Acclarent, Inc. Frontal sinus spacer
US20100210901A1 (en) * 2004-04-21 2010-08-19 Acclarent, Inc. Devices, Systems and Methods For Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose and/or Throat
US9055965B2 (en) 2004-04-21 2015-06-16 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8961398B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US8961495B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8080000B2 (en) 2004-04-21 2011-12-20 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8088101B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8090433B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US20100174308A1 (en) * 2004-04-21 2010-07-08 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8945088B2 (en) 2004-04-21 2015-02-03 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8114062B2 (en) 2004-04-21 2012-02-14 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8123722B2 (en) 2004-04-21 2012-02-28 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8142422B2 (en) 2004-04-21 2012-03-27 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8870893B2 (en) 2004-04-21 2014-10-28 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US9649477B2 (en) 2004-04-21 2017-05-16 Acclarent, Inc. Frontal sinus spacer
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8425457B2 (en) 2004-04-21 2013-04-23 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorder of the ears, nose and/or throat
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US8852143B2 (en) 2004-04-21 2014-10-07 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8828041B2 (en) 2004-04-21 2014-09-09 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8721591B2 (en) 2004-04-21 2014-05-13 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US9826999B2 (en) 2004-04-21 2017-11-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764726B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US20060063973A1 (en) * 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US7645272B2 (en) 2004-04-21 2010-01-12 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US10034682B2 (en) 2004-04-21 2018-07-31 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US20100114066A1 (en) * 2004-08-04 2010-05-06 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039657B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039680B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9084876B2 (en) 2004-08-04 2015-07-21 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
WO2006037837A1 (en) * 2004-10-01 2006-04-13 Turun Yliopisto Dye particle and its preparation and use
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US20090028923A1 (en) * 2005-01-18 2009-01-29 Acclarent, Inc. Implantable Devices and Methods for Treating Sinusitis and Other Disorders
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US20070208301A1 (en) * 2005-06-10 2007-09-06 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8968269B2 (en) 2005-09-23 2015-03-03 Acclarent, Inc. Multi-conduit balloon catheter
US9050440B2 (en) 2005-09-23 2015-06-09 Acclarent, Inc. Multi-conduit balloon catheter
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US20090171301A1 (en) * 2005-09-23 2009-07-02 Becker Bruce B Multi-conduit balloon catheter
US20070073269A1 (en) * 2005-09-23 2007-03-29 Becker Bruce B Multi-conduit balloon catheter
US9999752B2 (en) 2005-09-23 2018-06-19 Acclarent, Inc. Multi-conduit balloon catheter
US20070179518A1 (en) * 2006-02-02 2007-08-02 Becker Bruce B Balloon Catheters and Methods for Treating Paranasal Sinuses
US20080125720A1 (en) * 2006-05-17 2008-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9629656B2 (en) 2006-05-17 2017-04-25 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9198736B2 (en) 2006-05-17 2015-12-01 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US20080015448A1 (en) * 2006-06-22 2008-01-17 Keely Patricia J Stromal collagen in the diagnosis and characterization of breast cancer
US7805183B2 (en) 2006-06-22 2010-09-28 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
US20090240112A1 (en) * 2006-09-15 2009-09-24 Acclarent, Inc. Methods and Devices for Facilitating Visualization In a Surgical Environment
US9603506B2 (en) 2006-09-15 2017-03-28 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US20090240237A1 (en) * 2006-09-15 2009-09-24 Acclarent Inc. Methods and Devices for Facilitating Visualization In a Surgical Environment
US9179823B2 (en) 2006-09-15 2015-11-10 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US20090030274A1 (en) * 2006-09-15 2009-01-29 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8144966B2 (en) 2007-03-02 2012-03-27 Wisconsin Alumni Research Foundation Use of endogenous fluorescence to identify invading metastatic breast tumor cells
WO2008109414A3 (en) * 2007-03-02 2008-12-04 Wisconsin Alumni Res Found Use of endogenous fluorescence to identify invading metastatic breast tumor cells
US20080212867A1 (en) * 2007-03-02 2008-09-04 Provenzano Paolo P Use of Endogenous Fluorescence to Identify Invading Metastatic Breast Tumor Cells
US8118757B2 (en) * 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US9615775B2 (en) 2007-04-30 2017-04-11 Acclarent, Inc. Methods and devices for ostium measurements
US20080269643A1 (en) * 2007-04-30 2008-10-30 John Morriss Methods and devices for ostium measurement
US9463068B2 (en) 2007-05-08 2016-10-11 Acclarent, Inc. Methods and devices for protecting nasal turbinates
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US20090030409A1 (en) * 2007-07-27 2009-01-29 Eric Goldfarb Methods and devices for facilitating visualization in a surgical environment
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US9861793B2 (en) 2008-03-10 2018-01-09 Acclarent, Inc. Corewire design and construction for medical devices
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US9750401B2 (en) 2008-07-30 2017-09-05 Acclarent, Inc. Paranasal ostium finder devices and methods
US9636258B2 (en) 2009-03-31 2017-05-02 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US20100305697A1 (en) * 2009-03-31 2010-12-02 Acclarent, Inc. System and Method For Treatment of Non-Ventilating Middle Ear by Providing a Gas Pathway Through the Nasopharynx
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US20110160740A1 (en) * 2009-12-28 2011-06-30 Acclarent, Inc. Tissue Removal in The Paranasal Sinus and Nasal Cavity
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
WO2013123285A1 (en) * 2012-02-17 2013-08-22 Pharmacophotonics, Inc. Compositions and methods for monitoring biometric indicators
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis

Also Published As

Publication number Publication date Type
CA2418206A1 (en) 2002-01-24 application
WO2002005858A3 (en) 2003-07-24 application
WO2002005858A2 (en) 2002-01-24 application
EP1427451A2 (en) 2004-06-16 application
US6440389B1 (en) 2002-08-27 grant
JP2004517041A (en) 2004-06-10 application

Similar Documents

Publication Publication Date Title
Winkelman The distribution of tetraphenylporphinesulfonate in the tumor-bearing rat
Zenkevich et al. Photophysical and photochemical properties of potential porphyrin and chlorin photosensitizers for PDT
Frangioni In vivo near-infrared fluorescence imaging
Lewis et al. Small animal imaging: current technology and perspectives for oncological imaging
Sessler et al. Texaphyrins: synthesis and applications
Licha et al. Hydrophilic Cyanine Dyes as Contrast Agents for Near‐infrared Tumor Imaging: Synthesis, Photophysical Properties and Spectroscopic In vivo Characterization¶
US4341957A (en) Fluorescent antibody composition for immunofluorometric assay
Achilefu et al. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging
Reddy et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors
US6534041B1 (en) Acid-labile and enzymatically divisible dye compounds for diagnosis with near infrared light and for therapy
Zhang et al. Pyropheophorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters
Lebedev et al. Dendritic phosphorescent probes for oxygen imaging in biological systems
US6362175B1 (en) Porphyrin compounds for imaging tissue oxygen
US6926885B2 (en) In-vivo diagnostic method by means of near infrared radiation
Mewis et al. Biomedical applications of macrocyclic ligand complexes
Louie et al. In vivo visualization of gene expression using magnetic resonance imaging
Mik et al. Mitochondrial PO 2 measured by delayed fluorescence of endogenous protoporphyrin IX
US5877165A (en) Boronated porhyrins and methods for their use
Parker et al. Getting excited about lanthanide complexation chemistry
Marti et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer
Becker et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands
Garimella et al. Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium complexes
Celli et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization
US7510699B2 (en) In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
Liu et al. Metal coordination in photoluminescent sensing

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENERAL HOSPITAL CORPORATION, THE, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RABITO, CARLOS;REEL/FRAME:013237/0581

Effective date: 20000829